Page 62 - AN-3-2

Advanced Neurology

REVIEW ARTICLE
Inflammation in ischemic stroke patients with

type 2 diabetes – Part II: Potential therapeutic
targets

2,3
1
Liqun Zhang * , Ying Chen , Jingxian Xu , Christopher P. Corpe ,
4
2,3
Anan Shtaya , Philip Benjamin , and Yun Xu 2,3,7,8,9
6
5
1 Department of Neurology, St George’s University Hospital, London, United Kingdom
2 Department of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School,
Nanjing University, Nanjing, Jiangsu, China
3 Department of Neurology, Nanjing Drum Tower Hospital, State Key Laboratory of Pharmaceutical
Biotechnology and Institute of Translational Medicine for Brain Critical Diseases, Nanjing University,
Nanjing, Jiangsu, China
4 Department of Nutritional Sciences, School of Life Courses and Population Sciences, King’s
College London, London, United Kingdom
5 Head of Neuroscience at Arab Hospitals Group, Ramallah, Palestine
6 Department of Neuroradiology, St George’s University Hospital, London, United Kingdom
7 Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing,
Jiangsu, China
8 Jiangsu Provincial Key Discipline of Neurology, Nanjing, Jiangsu, China
9 Nanjing Neurology Medical Center, Nanjing, Jiangsu, China
(This article belongs to Special Issue: Advances in stroke research and therapy)

Part I of this review can be
accessed at doi: 10.36922/an.1683 Abstract
*Corresponding author:
Liqun Zhang Stroke is the leading cause of disability and the second leading cause of death
(Liqun.zhang@stgeorges.nhs.uk)
worldwide. Diabetes mellitus is an important independent cardiovascular risk factor
Citation: Zhang L, Chen Y, Xu J, in patients, regardless of age, smoking habit, and hypertension. Approximately one-
et al. Inflammation in ischemic
stroke patients with type 2 diabetes third of first-time ischemic stroke patients have diabetes. Inflammation is among
– Part II: Potential therapeutic the most important pathological mechanisms in atheroma formation, the damage
targets. Adv Neuro. 2024;3(2):1694. cascades of the acute phase, as well as during the subacute and chronic phases after
doi: 10.36922/an.1694 stroke. Diabetes, as a common risk factor for stroke, is often present for a long time
Received: August 28, 2023 before a stroke occurs, causing low-grade inflammation, and disrupting the proper
Accepted: February 27, 2024 functioning of the neurovascular units. These proinflammatory processes and
maladaptive immune mechanisms are further accelerated after cerebral ischemia
Published Online: June 4, 2024 and worsen the stroke outcome in diabetic patients. Clinical treatments for ischemic
Copyright: © 2024 Author(s). stroke are currently focused on restoring cerebral blood flow (reperfusion) in the
This is an Open-Access article acute phase, including thrombolysis and mechanical thrombectomy, which are not
distributed under the terms of the
Creative Commons Attribution applicable to patients that fall outside of the treatment window and/or without large-
License, permitting distribution, vessel occlusion. There are few approved treatments targeting cellular injury caused
and reproduction in any medium, by inflammation. There are even fewer data on effective treatment for diabetic stroke
provided the original work is
properly cited. targeting inflammation. This paper presents the second part of a review focusing on
the potential therapeutic targets in stroke patients with type 2 diabetes.
Publisher’s Note: AccScience
Publishing remains neutral with
regard to jurisdictional claims in
published maps and institutional Keywords: Stroke; Diabetes; Inflammation; Pathophysiology; Therapeutics
affiliations.

Volume 3 Issue 2 (2024) 1 doi: 10.36922/an.1694